More on JAZZ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $214.65 |
|
|||
| Open | $213.09 | ||||
| 52 Wk High | $160.00 | ||||
| 52 Wk Low | $95.80 | ||||
| Day High | $215.35 | ||||
| Day Low | $211.49 | ||||
| P/E | 39.78 | ||||
| EPS | $5.38 | ||||
| Volume | 560,600 | ||||
- Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
- Jazz Pharmaceuticals (JAZZ) PT Lowered to $314 at Morgan Stanley
- Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
- U.S. biotech SMids: Q3 earnings preview
- Form 8-K Jazz Pharmaceuticals For: Oct 06
- Form 144 Jazz Pharmaceuticals Filed by: ORiordan Anne
- Jazz Pharmaceuticals (JAZZ) PT Lowered to $296 at RBC Capital
- Form 4 Jazz Pharmaceuticals For: Oct 06 Filed by: GALA RENEE D
- Jazz Pharmaceuticals (JAZZ) PT Raised to $286 at Truist Securities
Entities mentioned with JAZZ
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
